Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor
Related Experiment Video
Updated: Oct 11, 2026

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
1Laboratory of Molecular Oncology, Tsukuba Life Science Center, Institute of Physical and Chemical Research, Ibaraki, Japan.
Abstract:
Retrovirus protease is an enzyme that cleaves gag and gag-pol precursor polyproteins into the functional proteins of mature virus particles. The correct processing of precursor polyproteins is necessary for the infectivity of virus particles: in vitro mutagenesis which introduces deletions into the murine leukaemia virus genome produces a protease-defective virus of immature core form and lacking infectivity. A therapeutic drug effective against disease caused by retrovirus proliferation could likewise interfere with virus maturation. The primary structure has so far been determined for the protease of avian myeloblastosis virus, and of murine, feline and bovine leukaemia viruses. Amino acid sequencing of the retrovirus proteases, either after their purification or from prediction from the nucleotide sequence, shows that they possess the Asp-Thr-Gly sequence characteristic of the aspartyl proteinases. In this report we show that retrovirus proteases belong to the aspartyl proteinase group and demonstrate an inhibition by the aspartyl proteinase-specific inhibitor, pepstatin A, on the activity of bovine leukaemia, Moloney murine leukaemia and human T-cell leukaemia virus proteases.
Insights
Retrovirus proteases are essential for viral maturation and infectivity. This study confirms retroviral proteases are aspartyl proteinases, inhibited by pepstatin A, suggesting therapeutic potential.
Area of Science:
- Biochemistry
- Virology
- Molecular Biology
Background:
- Retrovirus protease is crucial for cleaving viral polyproteins into functional proteins, enabling mature virus particle formation.
- Protease activity is essential for retroviral infectivity; protease-defective viruses are immature and non-infectious.
- Developing therapeutic drugs targeting retroviral proliferation requires understanding and potentially inhibiting virus maturation.
Purpose of the Study:
- To confirm that retrovirus proteases belong to the aspartyl proteinase group.
- To investigate the inhibitory effect of pepstatin A, an aspartyl proteinase-specific inhibitor, on retrovirus protease activity.
- To explore the potential of targeting retrovirus proteases as a therapeutic strategy.
Main Methods:
- Amino acid sequencing of purified retrovirus proteases and prediction from nucleotide sequences.
- Enzyme activity assays on bovine leukaemia virus, Moloney murine leukaemia virus, and human T-cell leukaemia virus proteases.
- Inhibition assays using pepstatin A, a known aspartyl proteinase inhibitor.
Main Results:
- Amino acid sequencing revealed the characteristic Asp-Thr-Gly sequence in retrovirus proteases, indicative of aspartyl proteinases.
- Pepstatin A significantly inhibited the enzymatic activity of bovine leukaemia, Moloney murine leukaemia, and human T-cell leukaemia virus proteases.
- These findings confirm retroviral proteases as members of the aspartyl proteinase family.
Conclusions:
- Retrovirus proteases are confirmed as aspartyl proteinases based on structural and functional evidence.
- The susceptibility of retrovirus proteases to pepstatin A highlights their potential as therapeutic targets for antiviral drug development.
- Interfering with retrovirus protease activity offers a viable strategy for combating diseases caused by retrovirus proliferation.
More Related Videos
08:01Detection of Human Immunodeficiency Virus Type 1 (HIV-1) Antisense Protein (ASP) RNA Transcripts in Patients by Strand-Specific RT-PCR
Published on: November 27, 2019
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly